View Author
stent patient death stent thrombosis trial thrombosis id-tlr spirit randomized paclitaxel-eluting artery lesion everolimu 2- year rates stent system paclitaxel-eluting stents paclitaxel-eluting stents jacc treatment syndrome study 2 years infarction xience outcome artery lesions everolimus-eluting cohort artery disease ef ficacy analysis drug-eluting table event ratio randomized trials finite revascularization intervention hazard cad cohorts planer stent type system eluting evaluation everolimus-eluting stents october –15 safety angina research consortium syndrome acuity hazard ratios stemi 0.01 figure ͻ0.0001 disease baseline boston scienti fic follow-up characteristic stone research ficacy abbreviation value target spirit trials bare-metal stents abbott 30 days scienti fidence interval signi curve boston reduction cardiol diameter
1 Most Recent Publications
|
Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: Pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) trials
(Article)
Planer, D. Smits, P.C. Kereiakes, D.J. Kedhi, E. Fahy, M. Xu, K. Serruys, P.W.J.C. Stone, G.W. |
2011-10-01
|